# A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate

> **NCT03257852** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 66 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** ASP5094
- **DRUG:** Placebo
- **OTHER:** Methotrexate therapy

## Key facts

- **NCT ID:** NCT03257852
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-29
- **Primary completion:** 2018-09-19
- **Final completion:** 2018-10-16
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03257852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03257852, "A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03257852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*